MAESTrO: Call for patient input on a submission from Hospira for a subsequent entry biologic

Posted by Michael Wonder on 11 Mar 2016

Call for patient input on a submission from Hospira for a subsequent entry biologic

11 March 2016 - CADTH has received notice of a pending submission from Hospira for Inflectra (infliximab) for the treatment of patients with Crohn’s disease or ulcerative colitis.

For more details, go to: https://www.cadth.ca/infliximab-19

Posted by:

Michael Wonder

Posted in:

Medicine , Health technology assessment , Canada , Submission , Biosimilar